Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
The evolution from single to triple agonism The trajectory of incretin-based obesity pharmacotherapy shows a clear pattern of increasing complexity and efficacy: First generation (single agonist): Liraglutide (Saxenda) and semaglutide (Wegovy) target GLP-1 only
Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD et al
Provider-Reviewed Reviewed and prescribed by an independent network of US-licensed providers
They compared them with a matched control group of 12,812 patients who didn't receive these medications
Published: Jun 5, 2026 Written by Klarity Editorial Team Published: Jun 5, 2026 Aetna plans in Arizona may cover weight loss treatment, including GLP-1 obesity medications, under your health benefits, depending on your specific plan, deductible status, and in-network provider selection
US$ 27.96
US$ 23.71
US$ 26.87
US$ 23.98
US$ 21.87
US$ 25.84
